Just a few questions. Once again on albuterol. Given that we have a 19.5% market share, what is the kind of revenue outlook that we can expect from this drug? And how much is it contributing to our North America revenue currently?
Questions across 1 call
Maitri Sheth
Choice Institutional Equities